ArticleInnere Medizin (Heidelberg, Germany)2025
[Update on pneumonia-Clinical management 2025 in consideration of the current guidelines].
Article in Innere Medizin (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- [Respiratory syncytial virus-not only relevant for hygienic reasons].Innere Medizin (Heidelberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumonia is one of the most frequent infectious diseases that lead to hospitalization. It is a decisive turning point and frequently leads to death, particularly in old and comorbid people (so-called terminal event). It is classified into community-acquired pneumonia, hospital-acquired pneumonia and pneumonia due to severe immunosuppression. The three entities differ especially in the spectrum of pathogens to be expected, the site of development and therefore in the calculated anti-infective treatment and initial diagnostics. The continuous re-evaluation of the course and the focal points as well as adaptation of the treatment are essential for the optimal outcome of the patient. Even after surviving an acute disease, in cases of possibly deteriorated functional status there is a need for good aftercare with management of comorbidities, social interventions and when necessary, treatment of persisting organ dysfunction. Prophylaxis by vaccination is essential.
Indexed as
Identifiers
40111446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.